{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:45:01Z","timestamp":1783460701758,"version":"3.55.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Consensus United States cervical cancer screening guidelines recommend use of combination Pap plus human papillomavirus (HPV) testing for women aged 30 to 65 years. An HPV test was approved by the Food and Drug Administration in 2014 for primary cervical cancer screening in women age 25 years and older. Here, we present the results of clinical-economic comparisons of Pap plus HPV mRNA testing including genotyping for HPV 16\/18 (co-testing) versus DNA-based primary HPV testing with HPV 16\/18 genotyping and reflex cytology (HPV primary) for cervical cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A health state transition (Markov) model with 1-year cycling was developed using epidemiologic, clinical, and economic data from healthcare databases and published literature. A hypothetical cohort of one million women receiving triennial cervical cancer screening was simulated from ages 30 to 70 years. Screening strategies compared HPV primary to co-testing. Outcomes included total and incremental differences in costs, invasive cervical cancer (ICC) cases, ICC deaths, number of colposcopies, and quality-adjusted life years for cost-effectiveness calculations. Comprehensive sensitivity analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In a simulation cohort of one million 30-year-old women modeled up to age 70 years, the model predicted that screening with HPV primary testing instead of co-testing could lead to as many as 2,141 more ICC cases and 2,041 more ICC deaths. In the simulation, co-testing demonstrated a greater number of lifetime quality-adjusted life years (22,334) and yielded $39.0 million in savings compared with HPV primary, thereby conferring greater effectiveness at lower cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Model results demonstrate that co-testing has the potential to provide improved clinical and economic outcomes when compared with HPV primary. While actual cost and outcome data are evaluated, these findings are relevant to U.S. healthcare payers and women's health policy advocates seeking cost-effective cervical cancer screening technologies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2015.5708","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T16:40:13Z","timestamp":1459269613000},"page":"606-616","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":35,"title":["The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis"],"prefix":"10.1177","volume":"25","author":[{"given":"Juan C.","family":"Felix","sequence":"first","affiliation":[{"name":"University of Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lacey","sequence":"additional","affiliation":[{"name":"Truven Health Analytics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Miller","sequence":"additional","affiliation":[{"name":"Truven Health Analytics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Lenhart","sequence":"additional","affiliation":[{"name":"Truven Health Analytics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Hofstra North Shore-LIJ School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Truven Health Analytics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"e_1_3_3_3_2","unstructured":"American Cancer Society. Cancer Facts and Figures. 2015. Available at: www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2015\/index. Accessed January8 2015."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1779-1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv342"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju153"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21544"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTGD94EVRSJCG"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000632"},{"key":"e_1_3_3_10_2","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves first human papillomavirus test for primary cervical cancer screening. FDA News Release 2014. Available at: www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm394773.htm. Accessed June10 2015."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.01.008"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta18230"},{"key":"e_1_3_3_14_2","unstructured":"Health and Social Care Information Centre (HSCIC). Cervical screening coverage: Lowest levels amongst women under 30. HSCIC News Archive 2014. Available at: www.hscic.gov.uk\/article\/5215\/Cervical-screening-coverage-lowest-levels-amongst-women-under-30. Accessed June10 2015."},{"key":"e_1_3_3_15_2","unstructured":"Millions of U.S. women are not getting screened for cervical cancer. CDC Newsroom Releases 2014. Available at: www.cdc.gov\/media\/releases\/2014\/p1105-vs-cervical-cancer.html. Accessed June10 2015."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-014-0135-4"},{"key":"e_1_3_3_17_2","unstructured":"College of American Pathologists (CAP). Human papillomavirus for cytology laboratories CHPVD CHPVM CHPVK CHPVJ Participant Summary. Washington DC: CAP 2015."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e3182616241"},{"key":"e_1_3_3_19_2","unstructured":"National Association of Nurse Practitioners in Women's Health (NPWH). HCP Cervical Cancer Survey. Washington DC: NPWH 2015."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000008"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2014.01.001"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.12.022"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_3_3_24_2","unstructured":"Kulasingam SL Havrilesky L Ghebre R Myers ER. Screening for cervical cancer: A decision analysis for the U.S. Preventive Services Task Force. Evidence Syntheses 86s. Rockville MD: Agency for Healthcare Research and Quality 2011."},{"key":"e_1_3_3_25_2","unstructured":"Centers for Disease Control and Prevention (CDC). Vital signs: Cervical cancer is preventable. Atlanta: CDC 2014. Available at: www.cdc.gov\/vitalsigns\/pdf\/2014-11-vitalsigns.pdf. Accessed March9 2016."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1090198114557124"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu159"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010166"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.11.020"},{"key":"e_1_3_3_30_2","unstructured":"Hologic Inc. ThinPrep\u00ae Imaging System summary of safety and effectiveness data. Premarket approval application (PMA) number P020002. June 6 2003."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000143"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25726"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01013-15"},{"key":"e_1_3_3_34_2","unstructured":"Hologic Inc. Aptima\u00ae HPV Assay package insert #503789 Rev A. Marlborough MA: Hologic 2013."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.07.004"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2010.00115"},{"key":"e_1_3_3_38_2","unstructured":"Howden LM Meyer JA. Age and sex composition: 2010. Census Briefs 2010. Washington DC: U.S. Department of Commerce U.S. Census Bureau 2011. Available at http:\/\/www.census.gov\/prod\/cen2010\/briefs\/c2010br-03.pdf Accessed March21 2016."},{"key":"e_1_3_3_39_2","first-page":"111","volume-title":"SEER survival monograph: Cancer survival among adults: US SEER Program 1988\u20132001, patient and tumor characteristics","author":"Kosary CL","year":"2007","unstructured":"Kosary CL. Cancer of the cervix uteri. In: LAG R, ed. SEER survival monograph: Cancer survival among adults: US SEER Program 1988\u20132001, patient and tumor characteristics. Bethesda, MD: National Cancer Institute SEER Program, 2007:111\u2013122."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000670"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-1353"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e670"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji115"},{"key":"e_1_3_3_44_2","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2014United States","volume":"63","author":"Stokley S","year":"2014","unstructured":"Stokley S, , Jeyarajah J, , Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2014United States. MMWR Morb Mortal Wkly Rep, 2014; 63:620\u2013624.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_45_2","unstructured":"US Social Security Administration. Actuarial Life Tables: Table 4.C6\u2014Period life table 2010. Available at: https:\/\/www.ssa.gov\/policy\/docs\/\u2026\/4c.xlsx. Accessed June10 2015."},{"key":"e_1_3_3_46_2","unstructured":"Howlander N Noone AM Krapcho M et al. SEER Cancer Statistics Review 1975\u20132012 National Cancer Institute. Bethesda MD. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2012\/. Accessed June10 2015."}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2015.5708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2015.5708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2015.5708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:36:26Z","timestamp":1780076186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2015.5708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1089\/jwh.2015.5708"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2015.5708","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}